Selinexor and Backbone Treatments of Multiple Myeloma Patients

This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to be evaluated are: * Arm 1: Selinexor + dexamethasone + pomalidomide (SPd); enrollment complete * Arm 2: Selinexor + dexamethasone + bortezomib (SVd); enrollment complete * Arm 3: Selinexor + dexamethasone + lenalidomide (SRd) in RRMM; enrollment complete * Arm 4: Selinexor + dexamethasone + pomalidom

Trial Details

NCT ID
NCT02343042
Phase
PHASE1 / PHASE2
Sponsor
Karyopharm Therapeutics Inc
Status
RECRUITING
Cancer Type
Newly Diagnosed Multiple Myeloma
Interventions
  • Selinexor
  • Dexamethasone
  • Lenalidomide
  • Pomalidomide
  • Bortezomib
  • Daratumumab
Locations (sample)
  • Gilbert, Arizona, United States|33.35283,-111.78903
  • Los Angeles, California, United States|34.05223,-118.24368
  • Denver, Colorado, United States|39.73915,-104.9847
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Written informed consent signed in accordance with federal, local, and institutional guidelines.
  • Age greater than or equal to (≥) 18 years at the time of informed consent.
  • Histologically confirmed diagnosis with measurable disease for relapsed/refractory myeloma.
  • Symptomatic MM, based on IMWG guidelines.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →